PROTECT for Rare Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill expands access to medications for rare diseases (those affecting 200,000 or fewer people in the US) across Medicare, Medicaid, and private insurance. For Medicare Part B, it adds coverage for drugs used to treat rare diseases when supported by peer-reviewed medical literature, as long as they are not listed as contraindicated. For Medicare Part D, it similarly expands coverage for rare disease drugs. For Medicaid, it rewrites the definition of "medically accepted indication" to include rare disease drug uses supported by peer-reviewed literature, clinical guidelines, or recognized medical experts, broadening what states must cover. For private insurance (group health plans under ERISA, the Public Health Service Act, and the Internal Revenue Code), it requires insurers to provide an expedited appeals process when they deny coverage for FDA-approved drugs used to treat rare diseases. All provisions take effect January 1, 2027.
Who Benefits and How
Patients with rare diseases benefit most directly, gaining broader access to medications that may be used off-label but are supported by clinical evidence. This is especially significant for rare disease patients, who often have few or no FDA-approved treatment options for their specific condition. Pharmaceutical companies that manufacture orphan drugs and rare disease treatments benefit from expanded coverage mandates across all major insurance types. Prescribing physicians benefit from reduced administrative barriers when prescribing evidence-based treatments for rare conditions. Medical societies gain a role in identifying expert-supported uses.
Who Bears the Burden and How
Medicare, Medicaid, and private insurance programs all face expanded coverage obligations, potentially increasing drug spending. State Medicaid programs must cover a broader range of rare disease drug uses. Health insurance companies and group health plan sponsors must implement new expedited appeals processes. The broader definition of medically accepted indication -- which includes expert opinion from medical societies, not just drug compendia -- could significantly expand the range of covered uses and associated costs.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Expands Medicare, Medicaid, Medicare Part D, and private insurance coverage of drugs used to treat rare diseases (affecting 200,000 or fewer individuals) by broadening the definition of medically accepted indication and requiring expedited appeals processes for coverage denials
Key Policy Areas
Healthcare, Pharmaceuticals, Rare Diseases, Insurance
Primary Purpose
Expands Medicare, Medicaid, Medicare Part D, and private insurance coverage of drugs used to treat rare diseases (affecting 200,000 or fewer individuals) by broadening the definition of medically accepted indication and requiring expedited appeals processes for coverage denials
Policy Domains
Medicaid - Expanded Medically Accepted Indication
Identified Gains
Contextual inference, no direct clause citation- Rare disease patients on Medicaid
- Orphan drug manufacturers
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- State Medicaid programs
- Federal Medicaid budget
Contextual inference, no direct clause citation
Medicare Part B - Coverage of Rare Disease Drugs
Identified Gains
Contextual inference, no direct clause citation- Rare disease patients on Medicare
- Rare disease drug manufacturers
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Medicare program budget
Contextual inference, no direct clause citation
Private Insurance - Expedited Appeals for Rare Disease Drugs
Identified Gains
Contextual inference, no direct clause citation- Rare disease patients with private insurance
- Prescribing physicians for rare diseases
- Rare disease pharmaceutical companies
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Health insurance companies
- Group health plans
- Employers sponsoring health plans
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Tillis (for himself and Mr. Heinrich) introduced the following …
Read twice and referred to the Committee on Finance.
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
Key Definitions
Terms defined in this bill
This Act may be cited as the Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act or the PROTECT for Rare Act.
Required process for group health plans and insurers to provide expedited review of coverage denials for FDA-approved drugs used to treat rare diseases, where use is supported by approved labeling or peer-reviewed literature.
A disease or condition affecting 200,000 or fewer individuals in the United States.
For drugs treating rare diseases, expanded to include uses supported by peer-reviewed medical literature, clinical guidelines, or an expert identified by a relevant medical society, provided the use is not listed as not indicated in drug compendia or listed as contraindicated in FDA-approved labeling.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology